Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1987 Sep;56(3):349–355. doi: 10.1038/bjc.1987.201

Second primary malignancy after Hodgkin's disease, ovarian cancer and cancer of the testis: a population-based cohort study.

M P Coleman 1, C M Bell 1, P Fraser 1
PMCID: PMC2002200  PMID: 3663481

Abstract

The risk of second primary malignancy was assessed in a population-based cohort study of all persons registered with Hodgkin's disease (n = 2,970), ovarian cancer (n = 11,802) and testicular cancer (n = 2,013) in the South Thames Cancer Registry during the period 1961-80, to identify for further study those second malignancies which might be treatment-related. A total of 244 second malignancies was observed. After adjustment for age, sex and calendar period, the relative risk of any second malignancy was 1.4 (90% confidence interval (CI) 1.1-1.7) after Hodgkin's disease, 1.1 (90% CI 1.0-1.2) after ovarian cancer and 0.7 (90% CI 0.5-1.0) after testicular cancer. In particular, the relative risk for leukaemia was 11.9 after Hodgkin's disease, 3.7 after ovarian cancer and 2.5 after testicular cancer. Excess risks were also observed for cancers of the cervix and lung after Hodgkin's disease, for cancers of the breast, lung and rectum after ovarian cancer, and for contralateral testicular cancer. Confounding by social class or smoking does not explain these observations. The excess risks of leukaemia and of second cancer were higher in patients first diagnosed with Hodgkin's disease and ovarian cancer in the 1970s than for those first diagnosed in the 1960s. Increased use of multiple-agent chemotherapy regimes for these tumours in the 1970s may have contributed to these increases in excess risk.

Full text

PDF
349

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berry G. The analysis of mortality by the subject-years method. Biometrics. 1983 Mar;39(1):173–184. [PubMed] [Google Scholar]
  2. Boice J. D., Jr, Greene M. H., Killen J. Y., Jr, Ellenberg S. S., Keehn R. J., McFadden E., Chen T. T., Fraumeni J. F., Jr Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med. 1983 Nov 3;309(18):1079–1084. doi: 10.1056/NEJM198311033091802. [DOI] [PubMed] [Google Scholar]
  3. Boice J. D., Jr, Monson R. R. Breast cancer in women after repeated fluoroscopic examinations of the chest. J Natl Cancer Inst. 1977 Sep;59(3):823–832. doi: 10.1093/jnci/59.3.823. [DOI] [PubMed] [Google Scholar]
  4. Breslow N. E. Elementary methods of cohort analysis. Int J Epidemiol. 1984 Mar;13(1):112–115. doi: 10.1093/ije/13.1.112. [DOI] [PubMed] [Google Scholar]
  5. Brody R. S., Schottenfeld D. Multiple primary cancers in Hodgkin's disease. Semin Oncol. 1980 Jun;7(2):187–201. [PubMed] [Google Scholar]
  6. Calabresi P. Leukemia after cytotoxic chemotherapy--a pyrrhic victory? N Engl J Med. 1983 Nov 3;309(18):1118–1119. doi: 10.1056/NEJM198311033091809. [DOI] [PubMed] [Google Scholar]
  7. Coleman M., Douglas A., Hermon C., Peto J. Cohort study analysis with a FORTRAN computer program. Int J Epidemiol. 1986 Mar;15(1):134–137. doi: 10.1093/ije/15.1.134. [DOI] [PubMed] [Google Scholar]
  8. Curtis R. E., Hankey B. F., Myers M. H., Young J. L., Jr Risk of leukemia associated with the first course of cancer treatment: an analysis of the Surveillance, Epidemiology, and End Results Program experience. J Natl Cancer Inst. 1984 Mar;72(3):531–544. [PubMed] [Google Scholar]
  9. Dieckmann K. P., Boeckmann W., Brosig W., Jonas D., Bauer H. W. Bilateral testicular germ cell tumors. Report of nine cases and review of the literature. Cancer. 1986 Mar 15;57(6):1254–1258. doi: 10.1002/1097-0142(19860315)57:6<1254::aid-cncr2820570632>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  10. Greene M. H., Boice J. D., Jr, Greer B. E., Blessing J. A., Dembo A. J. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. N Engl J Med. 1982 Dec 2;307(23):1416–1421. doi: 10.1056/NEJM198212023072302. [DOI] [PubMed] [Google Scholar]
  11. Grünwald H. W., Rosner F. Acute leukemia and immunosupressive drug use: a review of patients undergoing immunosuppressive therapy for non-neoplastic diseases. Arch Intern Med. 1979 Apr;139(4):461–466. [PubMed] [Google Scholar]
  12. Grünwald H. W., Rosner F. Acute myeloid leukemia following treatment of Hodgkin's disease: a review. Cancer. 1982 Aug 15;50(4):676–683. doi: 10.1002/1097-0142(19820815)50:4<676::aid-cncr2820500410>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  13. Haas J. F., Kittelmann B., Mehnert W. H., Staneczek W., Möhner M., Kaldor J. M., Day N. E. Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br J Cancer. 1987 Feb;55(2):213–218. doi: 10.1038/bjc.1987.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hay J. H., Duncan W., Kerr G. R. Subsequent malignancies in patients irradiated for testicular tumours. Br J Radiol. 1984 Jul;57(679):597–602. doi: 10.1259/0007-1285-57-679-597. [DOI] [PubMed] [Google Scholar]
  15. Kaldor J. M., Day N. E., Band P., Choi N. W., Clarke E. A., Coleman M. P., Hakama M., Koch M., Langmark F., Neal F. E. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer. 1987 May 15;39(5):571–585. doi: 10.1002/ijc.2910390506. [DOI] [PubMed] [Google Scholar]
  16. Kennedy B. J., Loeb V., Jr, Peterson V. M., Donegan W. L., Natarajan N., Mettlin C. National survey of patterns of care for Hodgkin's disease. Cancer. 1985 Dec 1;56(11):2547–2556. doi: 10.1002/1097-0142(19851201)56:11<2547::aid-cncr2820561102>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  17. Kinlen L. J., Sheil A. G., Peto J., Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J. 1979 Dec 8;2(6203):1461–1466. doi: 10.1136/bmj.2.6203.1461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Krause J. R., Ayuyang H. Q., Ellis L. D. Secondary non-hematopoietic cancers arising following treatment of hematopoietic disorders. Cancer. 1985 Feb 1;55(3):512–515. doi: 10.1002/1097-0142(19850201)55:3<512::aid-cncr2820550307>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  19. Maatman T., Bukowski R. M., Montie J. E. Retroperitoneal malignancies several years after initial treatment of germ cell cancer of the testis. Cancer. 1984 Nov 1;54(9):1962–1965. doi: 10.1002/1097-0142(19841101)54:9<1962::aid-cncr2820540929>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  20. McVie J. G., Somers R. Chemotherapy of Hodgkin's disease comes of age. Br Med J (Clin Res Ed) 1985 Mar 30;290(6473):950–951. doi: 10.1136/bmj.290.6473.950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Meadows A. T., Hobbie W. L. The medical consequences of cure. Cancer. 1986 Jul 15;58(2 Suppl):524–528. doi: 10.1002/1097-0142(19860715)58:2+<524::aid-cncr2820581319>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  22. Newlands E. S., Begent R. H., Rustin G. J., Parker D., Bagshawe K. D. Further advances in the management of malignant teratomas of the testis and other sites. Lancet. 1983 Apr 30;1(8331):948–951. doi: 10.1016/s0140-6736(83)92079-2. [DOI] [PubMed] [Google Scholar]
  23. Reimer R. R., Hoover R., Fraumeni J. F., Jr, Young R. C. Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med. 1977 Jul 28;297(4):177–181. doi: 10.1056/NEJM197707282970402. [DOI] [PubMed] [Google Scholar]
  24. Whitehouse J. M. Risk of leukaemia associated with cancer chemotherapy. Br Med J (Clin Res Ed) 1985 Jan 26;290(6464):261–263. doi: 10.1136/bmj.290.6464.261. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES